Program
telitacicept
Also written as “Telitacicept”, “RC18 160mg” and “RC18 240mg”.
Its studies are mostly in Lupus Erythematosus, Systemic · Glomerulonephritis, IGA · Myasthenia Gravis · Sjogren's Syndrome · Lymphoma, Follicular, led by 3 companies.
Drug pageTelitacicept: every studyAll 54 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| RemeGenits history only | 194 open or running | phase 3since Jan 8, 2017 | Aug 24, 2016 | Dec 31, 2026phase 3 · NCT07249632 |
| Vor Biopharma | 42 open or running | phase 3since Mar 23, 2022 | Mar 23, 2022 | Mar 2027phase 3 · NCT06456580 |
| Innovent Biologicsits history only | 22 open or running | phase 2since Sep 13, 2026 | Sep 13, 2026 | Jan 31, 2027phase 1 · NCT07886476 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Vor Biopharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2018Named telitaciceptINNProposed as its International Nonproprietary Name in WHO's List 120
- Mar 23, 2022First study: phase 3 study in Lupus Erythematosus, SystemicFirst studyNCT05306574 · 91 enrolled · United States, Argentina, Australia and more
- Jun 7, 20242 phase 3 studiesNCT06456580, NCT06456567
- Feb 4, 2026Phase 3 study in Sjogren's SyndromeNCT07404865 · 250 planned · United States, Georgia
Ahead
- Mar 2027Primary completion: phase 3 study in Myasthenia GravisNCT06456580
- Dec 2028Primary completion: phase 3 study in Sjogren's SyndromeNCT07404865
TargetBeta
“A fusion protein composed of the extracellular domain of human tumor necrosis factor receptor superfamily member 13B (TNFRSF13B; transmembrane activator and calcium modulator and cyclophilin ligand interactor; TACI) ”NCIt, by rule
Other programs on TNFRSF13B
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| povetaciceptrule | Vertex Pharmaceuticals | phase 3 | 9 |
| SHR-2173 | Jiangsu HengRui Medicine | phase 2 | 8 |
Studies
All 4 Vor Biopharma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07404865Sjogren's Syndrome · United States, Georgia | 3 | Recruiting | Dec 2028 | 250 |
| NCT06456580Myasthenia Gravis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Mar 2027 | 191 |
| NCT06456567Lupus Erythematosus, Systemic · United States | 3 | Withdrawn | Jan 2, 2025 | 0 |
| NCT05306574Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 3 | Terminated | Jan 6, 2025 | 91 |
How it is read
Names in the registry
- “Telitacicept”, 11 entries
- “RC18 160mg”, 3 entries
- “RC18 240mg”, 3 entries
- “RC18 240 mg”, 2 entries
- “RC18 160 mg”, 2 entries
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 6 studies
- Glomerulonephritis, IGA, 4 studies
- Myasthenia Gravis, 4 studies
- Sjogren's Syndrome, 3 studies
- Lymphoma, Follicular, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.